While investors flock to mass-market and electric vehicle stocks, Ferrari's unique strategy of cultivating scarcity and brand prestige has delivered enviable margins and pricing power. With shares well off their highs, analysts debate if now is the time to buy into this iconic automaker for the long haul.
H.C. Wainwright maintains a Buy rating on Lexeo Therapeutics but slashes its price target, citing persistent market doubts over the company's PKP2 cardiomyopathy program despite encouraging early clinical results.
From delivering pizzas to building a global sportswear empire, Ben Francis's journey to a $1.4 billion net worth is a modern business fable. Yet, in a candid podcast interview, the Gymshark CEO argues that equating self-worth with wealth is a 'wildly unproductive way to live,' offering a rare glimpse into the mindset behind the paper fortune.
Following the FDA's decision to remove the clinical hold on Intellia's Nex-Z hATTR-PN trial, analysts at Baird and H.C. Wainwright have significantly raised their price targets for the CRISPR gene-editing pioneer, citing reduced regulatory risk and a clearer path forward.
Wells Fargo boosts its price target for Taysha Gene Therapies (TSHA), citing strong progress in its pivotal Rett syndrome gene therapy program. The company has dosed the first patient in a key trial phase and received FDA alignment on its regulatory pathway.
Shares of the packaged food giant have slumped over the past year, raising questions about whether the stock is a bargain or a value trap. A deep dive into valuation metrics suggests significant upside potential.
IBM intensifies its focus on the enterprise AI market with the launch of its governed deployment platform, a strategic collaboration with e& for regulated sectors, and the appointment of PepsiCo's Ramon Laguarta to its board of directors.
In a move that deepens its cost leadership, Vanguard has reduced expense ratios on dozens of funds, marking the second major round of cuts under CEO Salim Ramji and highlighting the intense pressure on fees in the asset management industry.
Lawmakers reconvene Monday as House GOP leadership pushes for rapid passage of a stopgap funding bill to prevent a prolonged partial government shutdown, with tensions high over border security provisions.
Ryman Hospitality Properties has successfully expanded and extended its revolving credit facility to $850 million, providing the company with enhanced liquidity and revised covenants to navigate the evolving hospitality landscape and fund its long-term, experience-driven strategy.
Despite a robust 57% return over three years, a deep dive into Warby Parker's financials reveals a significant disconnect between its current share price and intrinsic value estimates, raising questions about its growth trajectory justifying the premium.
As tech giants scramble to curb soaring AI costs, a strategic pivot toward custom silicon is reshaping the competitive landscape, with Broadcom's design prowess and TSMC's manufacturing dominance creating a powerful new axis of influence.
Investment firm Giverny Capital has sold its position in auto-finance provider Credit Acceptance Corporation, citing a challenging market environment dominated by AI hype and large-cap tech outperformance. The move highlights a broader divergence between fundamental business performance and current investor sentiment.
A new federal loan aims to help the revived Buell Motorcycle Company scale production of its high-performance Super Cruiser, testing whether niche innovation can find a sustainable path in a competitive market.
Pharmaceutical giant Eli Lilly enters a strategic collaboration potentially worth up to $1.93 billion with biotech firm Repertoire Immune Medicines, aiming to develop precision treatments for autoimmune diseases that move beyond broad immunosuppression.
Analysts at Piper Sandler have increased their price target for Permian Basin-focused producer Diamondback Energy (FANG) to $218, maintaining an Overweight rating. The move comes as the firm anticipates solid Q4 results for gas-focused companies, while oil producers navigate a tougher pricing environment.
Amid a resilient but mixed market, companies with significant insider ownership are drawing investor attention. We examine three firms—spanning crypto, consumer staples, and finance—where management's substantial equity stakes align with ambitious earnings growth forecasts of up to 124%.
Private equity firm Exponent has halted the auction of UK accounting group Xeinadin after potential buyers refused to meet its £1bn valuation, signaling potential headwinds for deal-making in the professional services sector.
With the cost of living significantly higher than just a few years ago, Channel 11's Susan Koeppen offers actionable tips to help households reduce recurring bills and ease financial pressure.
BeOne Medicines extends its collaboration with quantitative systems pharmacology firm InSysBio, aiming to optimize clinical trial dosing and mitigate cytokine release syndrome risks across its broad portfolio of 15 novel oncology assets.
